Revive Therapeutics Ltd. (CVE:RVV) | WebDisclosure

Basculer en Français

10966	Companies
240146	Keywords
168912	Articles
129234	Press releases

Headlines Articles Press releases Revive Therapeutics Ltd.

Home
Companies
Revive Therapeutics Ltd.

PRESS RELEASE

published on 05/20/2026 at 13:45, 3 months 23 days ago

Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures
Revive Therapeutics Ltd. announces strategic expansion plan for bucillamine, a potential asset for infectious diseases, nerve-agent exposure, pandemics, and medical countermeasures. Company aims to advance preclinical studies and pursue government partnerships

Preclinical Studies Infectious Diseases Government Partnerships Bucillamine Revive Therapeutics
BRIEF

published on 03/11/2026 at 12:35, 6 months 1 day ago

Revive Therapeutics Expands Bucillamine's Patent Portfolio in North America

Patent Portfolio Infectious Diseases Bucillamine Nerve Agent Revive Therapeutics
BRIEF

published on 03/11/2026 at 12:35, 6 months 1 day ago

Revive Therapeutics étend le portefeuille de brevets de la bucillamine en Amérique du Nord

Portefeuille De Brevets Maladies Infectieuses Bucillamine Revive Therapeutics Agent Neurotoxique
PRESS RELEASE

published on 03/11/2026 at 12:30, 6 months 1 day ago

Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
Revive Therapeutics announces key patent milestones for Bucillamine in medical countermeasures and infectious diseases, strengthening its strategic position

Medical Countermeasures Infectious Diseases Bucillamine Revive Therapeutics Patent Milestones

Accesswire

Published on 09/12/2026 at 02:35, 16 hours 19 minutes ago

Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 19 hours 54 minutes ago

Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 20 hours 49 minutes ago

Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 21 hours 29 minutes ago

Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 1 day 1 hour ago

Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors

View all ACCESSWIRE

EQS Group

Published on 09/12/2026 at 17:50, 1 hour 4 minutes ago

New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 11 hours 24 minutes ago

NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 20 hours 39 minutes ago

Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 20 hours 44 minutes ago

Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 23 hours 9 minutes ago

DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031

Les Echos

Published on 09/11/2026 at 07:00, 1 day 11 hours ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 1 day 11 hours ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 1 day 11 hours ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 11 hours ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 23 hours ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE